226 related articles for article (PubMed ID: 7584508)
21. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
[TBL] [Abstract][Full Text] [Related]
22. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3].
Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M
Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843
[TBL] [Abstract][Full Text] [Related]
23. [T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release].
Chatenoud L; Bach JF
C R Seances Soc Biol Fil; 1991; 185(5):268-77. PubMed ID: 1806186
[TBL] [Abstract][Full Text] [Related]
24. Increase of sTNF receptor levels in acute renal allograft rejection after treatment with OKT3.
Bemelman FJ; Jansen J; van der Poll T; van Deventer SJ; ten Berge RJ
Nephrol Dial Transplant; 1994; 9(12):1786-90. PubMed ID: 7708265
[TBL] [Abstract][Full Text] [Related]
25. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
[TBL] [Abstract][Full Text] [Related]
26. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
27. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.
Eto M; Yoshikai Y; Nishimura Y; Hiromatsu K; Maeda T; Nomoto K; Kong YY; Kubo RT; Kumazawa J; Nomoto K
Immunology; 1994 Feb; 81(2):198-204. PubMed ID: 8157269
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of Fc receptor (Fc gamma RII) is reflected in cytokine release and adverse effects of mIgG1 anti-CD3/TCR antibody during rejection treatment after renal transplantation.
Tax WJ; Frenken LA; Glaudemans CA; Tamboer WP; Koene RA
Transplant Proc; 1995 Feb; 27(1):867-8. PubMed ID: 7879211
[No Abstract] [Full Text] [Related]
30. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
[TBL] [Abstract][Full Text] [Related]
31. Factors affecting therapeutic effect of anti-CD3 and CD4 monoclonal antibody in acute renal allograft rejection.
Wang XH; Xie T
Transplant Proc; 1996 Jun; 28(3):1306-8. PubMed ID: 8658671
[TBL] [Abstract][Full Text] [Related]
32. Increased dermal expression of ICAM-1 and VCAM-1 after administration of OKT3 in man.
Buysmann S; van Diepen FN; Surachno S; Pals ST; ten Berge RJ
Clin Nephrol; 1996 Aug; 46(2):84-91. PubMed ID: 8869784
[TBL] [Abstract][Full Text] [Related]
33. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
34. [Orthoclone OKT3 in the treatment of intractable acute renal allograft rejection].
Yu LX
Zhonghua Wai Ke Za Zhi; 1993 Dec; 31(12):754-5. PubMed ID: 8033708
[TBL] [Abstract][Full Text] [Related]
35. In vitro characterization of five humanized OKT3 effector function variant antibodies.
Xu D; Alegre ML; Varga SS; Rothermel AL; Collins AM; Pulito VL; Hanna LS; Dolan KP; Parren PW; Bluestone JA; Jolliffe LK; Zivin RA
Cell Immunol; 2000 Feb; 200(1):16-26. PubMed ID: 10716879
[TBL] [Abstract][Full Text] [Related]
36. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
37. Immunologic monitoring during OKT3 therapy.
Chatenoud L
Clin Transplant; 1993 Aug; 7(4 Pt 2):422-30. PubMed ID: 10146352
[TBL] [Abstract][Full Text] [Related]
38. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients.
Roayaie S; Sheiner PA; Emre S; Guy S; Schwartz ME; Boros P; Miller CM
Mediators Inflamm; 2000; 9(3-4):141-6. PubMed ID: 11132770
[TBL] [Abstract][Full Text] [Related]
39. In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TcR signaling.
Flamand V; Donckier V; Abramowicz D; Goldman M; Vandenabeele P; Urbain J; Moser M; Leo O
Cell Immunol; 1994 Aug; 157(1):239-48. PubMed ID: 8039247
[TBL] [Abstract][Full Text] [Related]
40. Using OKT3 to reverse cardiac allograft rejection.
Rogers KR; Sinnott JT; Ferguson JE
Heart Lung; 1989 Sep; 18(5):490-6. PubMed ID: 2506149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
